Trials / Not Yet Recruiting
Not Yet RecruitingNCT06589947
StOPping Hypertension and imprOving Children's Lives After KidnEy TranSplantation
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Hannover Medical School · Academic / Other
- Sex
- All
- Age
- 6 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Cardiovascular (CV) disease is a major morbidity in children after kidney transplantation (KTx), limiting life expectancy and impairing graft function. Arterial hypertension (AH) is the dominant CV risk factor, and highly abundant in this patient group. AH can cause left ventricular hypertrophy (LVH), which is predictive of CV death. LVH can be non-invasively assessed by measuring left ventricular mass index (LVMI). Analyses of observational data showed that blood pressure (BP) levels \<75th percentile (pct) were associated with a significant reduction of LVMI. Guidelines give BP goals for children with chronic kidney disease (CKD). No guidelines, however, exist on the treatment of AH in pediatric KTx patients. In the proposed multicenter, randomized, parallel group trial with blinded endpoint evaluation we aim to assess n=500 pediatric patients \>12 months after KTx at several KTx centers. Patients will be randomly assigned 1:1 to an intensified BP management group (BP target ≤60th pct) and a standard BP management group (BP target \<90th pct). The primary endpoint is LVMI after 24 months. Secondary endpoints are estimated glomerular filtration rate (eGFR), pulse wave velocity (PWV) and intima media thickness (IMT) after 24 months. BP control will be guaranteed for both groups through BP telemonitoring, which will be transmitted in real time to the treating physician and the trial's centralized BP office. By defining the adequate BP goal, the results of the proposed study will have direct implications for the care of children after KTx. The results will define an important element of post-KTx care and help to lower CV morbidity and subsequently CV mortality of pediatric KTx patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Intensified BP control | Treatment goal in the intensified group will be lowering BP ≤60th pct. |
| OTHER | Standard Treatment | Standard treatment is to achieve BP levels \<90th pct. |
Timeline
- Start date
- 2024-09-16
- Primary completion
- 2028-09-01
- Completion
- 2029-03-01
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Source: ClinicalTrials.gov record NCT06589947. Inclusion in this directory is not an endorsement.